Panoctine Plus Flydende middel Данія - данська - SEGES Landbrug & Fødevarer

panoctine plus flydende middel

rhône-poulenc agro a/s - guazatin, imazalil - flydende middel - 300 g/l guazatin ; 20 g/l imazalil

Panoctine Aqua Flydende middel Данія - данська - SEGES Landbrug & Fødevarer

panoctine aqua flydende middel

manglende oplysninger - guazatin, imazalil - flydende middel - 25 g/l guazatin ; 25 g/l imazalil

Panoctine Plus S Flydende middel Данія - данська - SEGES Landbrug & Fødevarer

panoctine plus s flydende middel

rhône-poulenc agro a/s - guazatin, imazalil - flydende middel - 300 g/l guazatin ; 20 g/l imazalil

Panoctine 30 Flydende middel Данія - данська - SEGES Landbrug & Fødevarer

panoctine 30 flydende middel

cyanamid danmark a/s - guazatin - flydende middel - 300 g/l guazatin

Intuniv Європейський Союз - данська - EMA (European Medicines Agency)

intuniv

takeda pharmaceuticals international ag ireland branch - guanfacinhydrochlorid - attention deficit disorder med hyperaktivitet - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv skal bruges som en del af et omfattende adhd behandling program, typisk, herunder psykologiske, pædagogiske og sociale foranstaltninger.

Azatin EC Emulsionskoncentrat Данія - данська - SEGES Landbrug & Fødevarer

azatin ec emulsionskoncentrat

mitsui agriscience international s.a./b.v. - azadirachtin - emulsionskoncentrat - 26 g/l azadirachtin

COVID-19 Vaccine (inactivated, adjuvanted) Valneva Європейський Союз - данська - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vacciner - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.